Seeking Alpha

Agenus launches dose-escalation study of AGEN1181 in solid tumors

|About: Agenus Inc. (AGEN)|By: , SA News Editor

Dosing is underway in a Phase 1 dose-escalation study evaluating Agenus' (NASDAQ:AGEN) AGEN1181 in patients with advanced solid tumors.

The first participants will receive AGEN1181 alone and in combination with a PD-1 inhibitor [AGEN2034 (balstilimab)].

AGEN1181 is an "Fc engineered" anti-CTLA-4 monoclonal antibody that binds to an Fc receptor, FcγRIIIA, found on antigen-presenting cells or natural killer cells, enhancing the therapeutic potential of anti-CTLA-4 therapy.

Try Seeking Alpha PREMIUM for unlimited analysis on AGEN